Overview
- Presents the recent advances in antibody engineering and in the various clinical applications
- An invaluable resource for both experts and those new to the field
- With contributions by international experts from research and biotech companies
- Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
About this book
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy.
In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.
Similar content being viewed by others
Keywords
Table of contents (19 chapters)
Editors and Affiliations
Bibliographic Information
Book Title: Bispecific Antibodies
Editors: Roland E. Kontermann
DOI: https://doi.org/10.1007/978-3-642-20910-9
Publisher: Springer Berlin, Heidelberg
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag Berlin Heidelberg 2011
Hardcover ISBN: 978-3-642-20909-3Published: 21 July 2011
Softcover ISBN: 978-3-642-43207-1Published: 13 December 2014
eBook ISBN: 978-3-642-20910-9Published: 21 July 2011
Edition Number: 1
Number of Pages: XVII, 373
Topics: Antibodies, Cancer Research, Oncology